ERGO methenolone enanthate injectable
100mg/ml, 10ml


Methenolone Enanthate is a clear, colorless oily sterile liquid for intramuscular use. Each ml contains 100 mg of methenolone enanthate.


Absorption is slow for the lipid-soluble esters such as the Cypionate or Enanthate and for oily solutions.

The anabolic steroids are highly protein bound, and are carried in plasma by a specific protein called sex-hormone binding globulin. The metabolism of absorbed drug is rapid, and the elimination half-life from plasma is very short. The duration of the biological effects is therefore determined almost entirely by the rate of absorption from injection site and removal of the ester part.

Free (de-esterified) anabolic androgens are metabolized by mixed function hepatic oxidases.

Indications and Usage

Methenolone enanthate is indicated for treatment of aplastic anemia, breast cancer and postmenopausal osteoporosis.


Hypersensitivity to the substance or excipients.


Dosage and administration

Recommended dose for osteoporosis is 100 mg every other week, reducing to once every 3 to 4 weeks after an initial response. Recommended dose for progressive breast cancer is 100 mg every 1 or 2 weeks or 200 mg every 2 to 3 weeks.


In palliative treatment of breast cancer, the therapy stops if after 3 months the condition resumes or hypocalcaemia is observed at any phase of the treatment.

Calcium serum and urine levels must be determined at regular intervals in women with metastasic breast carcinoma under the treatment with testosterone.

It is usually recommended to start the treatment with full doses and titrate according to patients individual characteristics.

Special caution should be given to patients with cardiac impairment, hypertension; renal failure, epilepsy, migraine, diabetes, bone metastasis; dysmenorrhea; dyslipidemia; coagulation disorders; porphyria.


-Hypersensitivity to methenolone.
-Concomitant use with oral anticoagulants.
-Breast cancer (male), prostate cancer or continued or suspected adenoma. -Severe heart, liver or kidney failure.
-In prepubertal individuals or individuals in aggressive state;
-Pregnancy,-active hypercalcemia.

Drug interactions

Androgens and anabolic steroids have been reported to enhance the activity of some drugs, resulting in increases of toxicity. Drugs affected include ciclosporin, levothyroxine, and anticoagulants such as warfarin. Resistance to the effects of neuromuscular blockers has also been reported. As androgens and anabolic steroids can alter glucose metabolism, doses of insulin or oral anti-diabetics may need adjustment.

Pregnancy and lactation

When administered to pregnant women, androgens cause virilization of the external genitalia of the female fetus. This virilization includes clitoromegaly, abnormal vaginal development, and fusion of genital folds to form a scrotal-like structure. The degree of masculinization is related to the amount of drug given and the age of the fetus, and is most likely to occur in the female fetus when the drugs are given in the first trimester. If a patient becomes pregnant while taking these drugs, she should be informed about the potential hazard to the fetus.

It is not known whether androgens are excreted in human milk.


Adverse effects

The adverse effects of anabolic steroids include weight gain, fluid retention, and abnormal liver function as measured by biochemical tests.

Administration to children can cause premature closure of the epiphyses.

Men can develop impotence and azoospermia. Women are at the risk of virilization.


Acute overdose can produce nausea and gastrointestinal problems.

Chronic usage can cause an increase in muscle bulk, exaggeration of male characteristics, and effects related to male hormones. Anabolic steroids can influence sexual function. They can also cause cardiovascular and hepatic damage. Acne and male-pattern baldness occur in both genders; irregular menses, atrophy of the breasts, and clitoromegaly in women; and testicular atrophy and prostatic hypertrophy in men.




1x10ml glass vial